OverviewSuggest Edit

Oramed Pharmaceuticals is a pharmaceutical company currently engaged in the research and development of innovative pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides.

TypePublic
Founded2006
HQNew York, NY, US
Websiteoramed.com

Latest Updates

Employees (est.) (Nov 2017)14(+17%)
Revenue (FY, 2019)$2.7 M(+11%)
Share Price (Feb 2021)$10.4 (+4%)
Cybersecurity ratingAMore

Key People/Management at Oramed Pharmaceuticals

Nadav Kidron

Nadav Kidron

Chief Executive Officer, President & Director
Miriam Kidron

Miriam Kidron

Chief Scientific Officer & Director
Josh Hexter

Josh Hexter

Chief Operating and Business Officer
Avi Gabay

Avi Gabay

CFO
Show more

Oramed Pharmaceuticals Office Locations

Oramed Pharmaceuticals has offices in New York and ירושלים
New York, NY, US (HQ)
1185 6th Ave #228
ירושלים, IL (HQ)
Hi-Tech Park
Show all (2)

Oramed Pharmaceuticals Financials and Metrics

Oramed Pharmaceuticals Revenue

Oramed Pharmaceuticals's revenue was reported to be $2.70 m in FY, 2019
USD

Revenue (Q1, 2021)

674.0k

Market capitalization (8-Feb-2021)

306.3m

Closing stock price (8-Feb-2021)

10.4

Cash (30-Nov-2020)

14.9m

EV

292.0m
Oramed Pharmaceuticals's current market capitalization is $306.3 m.
Annual
USDFY, 2012FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

641.0k2.5m2.4m2.7m

Cost of goods sold

490.0k187.0k90.0k

Gross profit

151.0k2.3m2.6m

Gross profit Margin, %

24%92%97%
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

125.0k163.0k(610.0k)611.0k(617.0k)611.0k604.0k617.0k674.0k666.0k682.0k674.0k674.0k681.0k674.0k

Cost of goods sold

187.0k86.0k35.0k55.0k

Gross profit

(797.0k)531.0k639.0k611.0k

Gross profit Margin, %

131%86%95%92%
Annual
USDFY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.4m2.3m3.2m3.9m4.0m5.0m3.3m

Accounts Receivable

87.7k58.4k

Prepaid Expenses

2.3k90.1k127.0k198.0k159.0k574.0k1.0m

Current Assets

5.3m8.6m17.4m31.2m20.3m31.0m33.3m
Quarterly
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.3m)(4.2m)(5.7m)(11.0m)(10.5m)(12.7m)(14.4m)

Depreciation and Amortization

14.7k5.4k6.0k4.0k4.0k5.0k6.0k8.0k

Accounts Payable

203.1k(146.2k)475.0k

Cash From Operating Activities

(2.3m)(3.4m)(4.1m)(4.9m)4.7m(5.8m)(14.7m)(12.9m)
USDQ1, 2012

Financial Leverage

1.2 x
Show all financial metrics

Oramed Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Oramed Pharmaceuticals Online and Social Media Presence

Embed Graph

Oramed Pharmaceuticals News and Updates

Thinking about buying stock in Hancock Jaffe, Oramed Pharmaceuticals, Tilray, Hexo Corp, or Arbutus Biopharma?

NEW YORK, Nov. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HJLI, ORMP, TLRY, HEXO, and ABUS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Oramed Pharmaceuticals Issues Letter to Shareholders

NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following letter to shareholders from Chief...

Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from the...

Oramed Pharmaceuticals Blogs

Oramed to Present at H.C. Wainwright Global Life Sciences Conference 2021

NEW YORK, March 4, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwr…

Oramed Issues Letter to Shareholders

- Recruiting and Dosing Patients Across Growing Number of U.S. Sites in Phase 3 Oral Insulin Trial - Clinical Advancements in NASH & Leptin - Discussions with Potential Partners Under Way - To view a video message from the CEO, click here NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Oramed Pharmaceut…

Times of Israel: Oral insulin, by Israeli mom-son team, starts final trials to become world’s 1st

“This has the potential to improve lives of hundreds of millions of diabetics worldwide,” Oramed CEO Nadav Kidron told The Times of Israel. “And by improving treatment it can reduce complications and, in turn, reduce the cost of treating diabetics.” Read more here.   The post Times of Israel: Oral i…

Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study

Randomization of patients in the world's first Phase 3 oral insulin study conducted under FDA approved protocol NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral…

Oramed Reports Positive First in Human Data from Oral Leptin Study

Leptin capsule may have a role in helping control and reduce obesity rates which are highly correlated with diabetes NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of…

Oramed Initiates Phase 2 NASH Trial of Oral Insulin

NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in a global trial of its oral insulin …
Show more

Oramed Pharmaceuticals Frequently Asked Questions

  • When was Oramed Pharmaceuticals founded?

    Oramed Pharmaceuticals was founded in 2006.

  • Who are Oramed Pharmaceuticals key executives?

    Oramed Pharmaceuticals's key executives are Nadav Kidron, Miriam Kidron and Josh Hexter.

  • How many employees does Oramed Pharmaceuticals have?

    Oramed Pharmaceuticals has 14 employees.

  • What is Oramed Pharmaceuticals revenue?

    Latest Oramed Pharmaceuticals annual revenue is $2.7 m.

  • What is Oramed Pharmaceuticals revenue per employee?

    Latest Oramed Pharmaceuticals revenue per employee is $193.1 k.

  • Who are Oramed Pharmaceuticals competitors?

    Competitors of Oramed Pharmaceuticals include Rani Therapeutics, SiNatur and Caelus Health.

  • Where is Oramed Pharmaceuticals headquarters?

    Oramed Pharmaceuticals headquarters is located at 1185 6th Ave #228, New York.

  • Where are Oramed Pharmaceuticals offices?

    Oramed Pharmaceuticals has offices in New York and ירושלים.

  • How many offices does Oramed Pharmaceuticals have?

    Oramed Pharmaceuticals has 2 offices.